Advertisement
U.S. markets closed

Allarity Therapeutics, Inc. (ALLR)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.3011-0.0178 (-5.58%)
At close: 04:00PM EDT
0.2950 -0.01 (-2.03%)
After hours: 06:46PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.3189
Open0.3201
Bid0.2240 x 200
Ask0.3798 x 200
Day's Range0.2900 - 0.3201
52 Week Range0.2900 - 154.4000
Volume348,992
Avg. Volume129,462
Market Cap1.86M
Beta (5Y Monthly)0.23
PE Ratio (TTM)N/A
EPS (TTM)-10.2600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ALLR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Allarity Therapeutics, Inc.
    Technical Assessment: Neutral in the Intermediate-TermWas that a case of quarter-end buying by institutions? Over the last 50 minutes of the trading session on Wednesday, the S&P 500 (SPX) took off like a rocket, surging 30 points and finishing 0.9% higher on the day and at another all-time high. But the biggest winners on the day were small-caps, with the Russell 2000 (IWM) surging 2.2% and the S&P 600 (SML) spiking 2.4%. The IWM is breaking out of a more-than two-year base and closed at its highest level since December 2021.
    Rating
    Fair Value
    Economic Moat
    20 hours agoArgus Research
View more
  • GlobeNewswire

    Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

    The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of IXEMPRA® and dovitinib is de-prioritizedThe Company has been able to reduce costs materially Boston (March 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced

  • GlobeNewswire

    Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

    Boston (March 25, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company has been granted a formal extension until April 24, 2024 to regain compliance under Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”) or any of the alternative requirements in Listing Rule 5550(b). The granting of the extension fol

  • GlobeNewswire

    Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

    Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive AdvisorReduced Net Loss from Operations by 50% and Reduced Net Loss by 26%Announced Data in December 2023 from Advanced Ovarian Cancer Phase 2 Stenoparib Study Showing Significant Clinical Benefit Boston (March 8, 2024) — Allarity Therapeutics, Inc. (“Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalize